| Literature DB >> 30187210 |
Tarcila Santos Datoguia1, Elvira Deolinda Rodrigues Pereira Velloso1, Ricardo Helman1, Juliane Garcez Musacchio2, Marco Aurélio Salvino3, Rodolfo Almeida Soares4, Marcia Higashi5, Adriana Valente Fadel6, Rodrigo Santucci Alves E Silva1, Nelson Hamerschlak1, Fabio Pires de Souza Santos1, Paulo Vidal Campregher7,8.
Abstract
Prognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML. We have analysed outcomes in 65 AML cases (median age of 54 years, range 18-82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis. We classified patients as favorable (N = 13), intermediate-1 (N = 25), intermediate-2 (N = 15), or adverse risk (N = 9). Bone marrow transplantation (BMT) was performed in 13 patients (21%). Median follow-up was 12 months. The median overall survival (OS) for all patients was 12.4 months. Median OS was 19.8, 12.4, 10.1, and 10.4 months (p = 0.24) for patients in the favorable, intermediate-1, intermediate-2, and adverse groups, respectively. Among patients receiving BMT, median OS was 26.8 months. The ELN is a valuable tool for prognostic stratification of AML patients treated in Brazil. Nevertheless, its usefulness is limited when compared to data from developed countries.Entities:
Keywords: Acute myeloid leukemia; Risk stratification; Stem cell transplantation; Survival
Mesh：
Year: 2018 PMID： 30187210 DOI： 10.1007/s12032-018-1179-3
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064